Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 280 participants.

Also called NCT05240781

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 280 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05240781
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05240781. Randomized; double masking; primary purpose treatment. Start 2021-09-29 (actual); primary completion 2024-02-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk
Acronym
ZEVS-HBR
Condition
High Bleeding Risk
Intervention (Device)
Zotarolimus eluting stent
Intervention (Device)
Sirolimus eluting stent
Lead sponsor
Instituto Nacional de Cardiologia Ignacio Chavez (class: other)

Record details

Record id
cardio:ct-nct05240781
Content hash
a608a22d0df4b6d511ac4bbec7dd0400e7c65b45c025a9ff9c28ba738cdb82fe